MIA contributes to major research breakthrough which pioneers a new way of treating cancer

MIA contributes to major research breakthrough which pioneers a new way of treating cancer

1 June 2015

 

Melanoma Institute Australia (MIA) has had a strong presence at the American Society of Clinical Oncology (ASCO) congress in Chicago; where the best ever results seen in metastatic melanoma treatment clinical trial have been presented. Two large international trials, to which MIA contributed, have shown that combinations of new melanoma drugs result in major improvements in disease control and patient survival compared to current therapy.

One study (CheckMate 067), presented in the plenary session, was the first phase 3 trial to combine modern immunotherapy drugs in any cancer. The trial demonstrated improvements in both tumour response and patient survival with the combination of ipilimumab (Yervoy®) with the PD-1 antibody nivolumab (Opdivo®) compared to either therapy given alone. This is not only a major advance for melanoma treatment, but provides the impetus to attempt this approach in other cancer types and with other drug combinations.

Updated results were presented from a second study of targeted therapy (COMBI-D), where a BRAF inhibitor (dabrafenib) was combined with a MEK inhibitor (trametinib) and compared to BRAF inhibitor treatment alone. Again, patients responded better and lived longer with better quality of life with the combination treatment, cementing this as the new standard targeted therapy treatment for metastatic melanoma for patients with BRAF-positive tumours.

Associate Professor Georgina Long of MIA and the University of Sydney, co-author on these studies,  says,  “Melanoma Institute Australia is leading the way and making major steps forward in cancer history.  Two large clinical trials presented at ASCO show that two drugs are better than one for improving patient outcome, both for targeted therapies and immunotherapies, and are the new way of treating cancer.”

In April an international study to which MIA contributed the highest number of patients found that the PD-1 antibody pembrolizumab (KEYTRUDA®) prolonged survival and had less high-grade toxicity compared with ipilimumab (YERVOY®) in patients with advanced melanoma, where melanoma has spread to distant parts of the body. The results from this latest announcement at ASCO prove that the combination of immunotherapy drugs is a better alternative for the majority of melanoma patients. 

“MIA has already broken ground with the PD-1 study that showed that the PD-1 antibody pembrolizumab is better than current treatments for patients with advance melanoma, reducing the size of tumours in 70% of patients and recording a one year survival rate of 74%  - where it had previously been 58%.  The latest findings of combination immunotherapies are the next level of how we treat not just melanoma, but cancer around the world,” Associate Professor Alex Guminski, Clinical Researcher and Consultant Medical Oncologist, Melanoma Institute Australia.

“The latest results are more great news for patients with melanoma, and have implications for all cancer patients.  By focusing on the science behind cancer, we can design further treatments that improve response and survival, and hopefully even cure some people,” says Assoc Professor Long.  

Help us continue our work. Donate now.

Australasian Melanoma Conference AMC2021
19 Nov - 20 Feb 2021

Australasian Melanoma Conference AMC2021

The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.

Predicting disease spread in thin melanoma
05 Mar 2021

Predicting disease spread in thin melanoma

A new MIA online risk calculator for clinicians can determine the likelihood of thin melanoma spreading.   

Tags: melanoma
Exploring our own clinical questions through MIA's new trials initiative
04 Mar 2021

Exploring our own clinical questions through MIA's new trials initiative

MIA has recently established a new division of our Clinical Trials Program which co-ordinates and manages investigator-led multi-centre trials. 

Tags: melanoma
Young researchers awarded Fellowships to pursue innovative treatments for melanoma
04 Mar 2021

Young researchers awarded Fellowships to pursue innovative treatments for melanoma

Two young researchers from MIA and The University of Sydney awarded Cancer Institute NSW fellowships.

Tags: melanoma
Young researchers receive boost to develop innovative treatment for melanoma
04 Mar 2021

Young researchers receive boost to develop innovative treatment for melanoma

Two young researchers from MIA and The University of Sydney awarded Cancer Institute NSW fellowships.

Tags: melanoma
Launch of Melanoma March 2021
01 Mar 2021

Launch of Melanoma March 2021

Aussies urged to leave their footprint on melanoma as efforts step up to save lives from the disease.

Tags: melanoma
WA Melanoma Community Forum
25 Mar 2021

WA Melanoma Community Forum

An evening for WA melanoma patients, carers and the wider melanoma community, where speakers will provide updates on melanoma research, treatment and support.  

Olivia Vivian announced as MIA ambassador
12 Feb 2021

Olivia Vivian announced as MIA ambassador

Olivia is using her Ninja star power to shine a spotlight on melanoma prevention - in memory of her dad. 

Tags: melanoma
Melanoma breakthrough - neoadjuvant treatment saving lives.
09 Feb 2021

Melanoma breakthrough - neoadjuvant treatment saving lives.

Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.

Tags: melanoma
Melanoma breakthrough - neoadjuvant therapy saving lives.
09 Feb 2021

Melanoma breakthrough - neoadjuvant therapy saving lives.

Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.

Tags: melanoma
Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
04 Feb 2021

Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?

New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.

Tags: melanoma
Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
04 Feb 2021

Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?

New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.

Tags: melanoma
A message to all Australians from melanoma patient Stuart Taylor
16 Dec 2020

A message to all Australians from melanoma patient Stuart Taylor

Stuart has advanced melanoma which is not responding to treatment. He has shared his story on ABC's 7:30 in the hope that others can escape the same fate. 

Tags: melanoma
Olivia Vivian nominates MIA as Charity Partner on Channel 9's Celebrity Apprentice.
02 Dec 2020

Olivia Vivian nominates MIA as Charity Partner on Channel 9's Celebrity Apprentice.

A Ninja Warrior legend and Olympic gymnast, Olivia knows first hand the devastating impact of melanoma.

Tags: melanoma
It's 'Game On Mole' this summer!
01 Dec 2020

It's 'Game On Mole' this summer!

All Australians are urged to join the fight against melanoma this summer. 

Tags: melanoma
Prof Richard Scolyer named Outstanding Cancer Researcher of the Year  
27 Nov 2020

Prof Richard Scolyer named Outstanding Cancer Researcher of the Year  

The ground-breaking work of MIA's Co-Medical Director Prof Richard Scolyer has been recognised with NSW’s highest accolade for cancer research. 

Tags: melanoma
Dr James Wilmott wins 2020 Wildfire Highly Cited Publication Award
24 Nov 2020

Dr James Wilmott wins 2020 Wildfire Highly Cited Publication Award

A landmark study led by MIA's Dr Willmott is making a difference to melanoma treatment around the globe.

Tags: melanoma
MIA researchers feature on prestigious Highly Cited Researchers 2020 List
18 Nov 2020

MIA researchers feature on prestigious Highly Cited Researchers 2020 List

The highly anticipated annual list is the “who’s who” of the scientific elite from across the globe.

Tags: melanoma
Game On Mole is back this summer!
13 Nov 2020

Game On Mole is back this summer!

The uniquely Aussie awareness campaign ‘Game On Mole’ is back for its second year – with a new look but same important message.

Tags: melanoma
RCPA recognition for Professor Richard Scolyer.
12 Nov 2020

RCPA recognition for Professor Richard Scolyer.

Professor Richard Scolyer receives The Royal College of Pathologists of Australasia Distinguished Fellow Award.

Tags: melanoma